Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Domperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.98 |
| ▸ | DRD3 | P35462 | 5/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.98 |
| ▸ | HTR1A | P08908 | 4/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | HTR2A | P28223 | 3/20 | 0.98 |
| ▸ | HRH1 | P35367 | 3/20 | 0.98 |
| ▸ | HTR2B | P41595 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Domperidone SCHEMBL29177488 | 1.00 | OPRM1 (0.98) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| Domperidone SCHEMBL11506647 | 0.99 | OPRM1 (0.96) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| Domperidone SCHEMBL29373565 | 0.99 | OPRM1 (1.00) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| Domperidone SCHEMBL43729 | 0.99 | OPRM1 (1.00) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| SCHEMBL11509148 | 0.99 | OPRM1 (1.00) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| Domperidone SCHEMBL27988838 | 0.98 | OPRM1 (0.98) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| Water SCHEMBL11508184 | 0.96 | DRD2 (0.94) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| Water SCHEMBL11508185 | 0.96 | DRD2 (0.94) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| Domperidone SCHEMBL11507534 | 0.95 | DRD2 (0.89) | OPRM1DRD2DRD3SLC6A4HTR1A | |
| SCHEMBL11507685 | 0.94 | DRD2 (0.90) | OPRM1DRD2DRD3SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000854-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | CHASE THERAPEUTICS CORPORATION (US) | 2022-01-06 | — | — | US | claimed |
| EP-3902543-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | Chase Therapeutics Corporation (US) | 2021-11-03 | — | — | EP | claimed |
| CN-113365629-A | Domperidone anti-neurodegenerative composition and application | 才思治疗公司 | 2021-09-07 | — | — | CN | claimed |
| WO-2020139520-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | CHASE THERAPEUTICS CORPORATION (US) | 2020-07-02 | — | — | WO | claimed |
| CN-112996788-B | Anthelmintic heterocyclic compounds | 勃林格殷格翰动物保健美国公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117580869-A | Cells expressing HER3 antigen binding molecules | 蜂鸟生物科技私人有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117545775-A | Cells expressing VISTA antigen binding molecules | 蜂鸟生物科技私人有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-112135639-B | Cell assembly mediated delivery of cancer immunotherapy checkpoint inhibitors | 北卡罗莱纳州立大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-116322693-A | Combination therapy | 辉瑞公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116157403-A | Morphology of treasiril and method for producing same | G1治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220000854-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | CHASE THERAPEUTICS CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3902543-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | Chase Therapeutics Corporation (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| CN-107106484-A | Gastric retention gel preparation | 雅戈泰克股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-8471011-B2 | Preparation of acid addition salts of amine bases by solid phase—gas phase reactions | APOTEX PHARMACHEM INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| EP-1856108-A1 | PREPARATION OF ACID ADDITION SALTS OF AMINE BASES BY SOLID PHASE-GAS PHASE REACTIONS | Apotex Pharmachem Inc. (CA) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205944-A1 | Preparation of acid addition salts of amine bases by solid phase-gas phase reactions | APOTEX PHARMACHEM INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006094395-A1 | PREPARATION OF ACID ADDITION SALTS OF AMINE BASES BY SOLID PHASE-GAS PHASE REACTIONS | APOTEX PHARMACHEM INC. (CA) | 2006-09-14 | — | — | WO | disclosed |
| US-4160836-A | Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-07-10 | — | — | US | disclosed |
| US-4126688-A | ANTIEMETIC 1-(BENZOTRIAZOLYL-ALKYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | DRD2 130/4885OPRM1 33/4885DRD3 207/4885 |
| US-20220000854-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | PARK7, HTT, TIA1 | DRD2 90/4885OPRM1 78/4885DRD3 529/4885 |
| US-20060205944-A1 | Preparation of acid addition salts of amine bases by solid phase-gas phase reactions | POLR2A, AVPR1B, AVPR2 | DRD2 211/4885OPRM1 65/4885DRD3 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.